Oxford BioDynamics (LON:OBD) Trading 38.5% Higher – Still a Buy?

Shares of Oxford BioDynamics Plc (LON:OBD) were up 38.5% on Tuesday . The company traded as high as GBX 0.40 ($0.01) and last traded at GBX 0.36 ($0.00). Approximately 34,668,625 shares were traded during trading, an increase of 95% from the average daily volume of 17,810,518 shares. The stock had previously closed at GBX 0.26 ($0.00).

Oxford BioDynamics Price Performance

The company has a current ratio of 0.68, a quick ratio of 2.80 and a debt-to-equity ratio of 370.22. The stock has a fifty day moving average of GBX 0.36 and a two-hundred day moving average of GBX 0.51. The stock has a market capitalization of £11.56 million, a price-to-earnings ratio of -0.11 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last issued its quarterly earnings results on Monday, June 30th. The biotechnology company reported GBX (0.70) (($0.01)) EPS for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.